Clarissa Desjardins net worth and biography

Clarissa Desjardins Biography and Net Worth

Director of Insmed

Dr. Desjardins has been a member of our board since November 2019, bringing more than 20 years of leadership experience in biotechnology, pharmaceuticals and research. Dr. Desjardins founded and has served as CEO of Congruence Therapeutics since 2021. Previously, she founded Clementia Pharmaceuticals Inc. (formerly Nasdaq: CMTA) and served as its President and Chief Executive Officer from 2011 until its acquisition by Ipsen S.A. in April 2019. From 2009 to 2011, Dr. Desjardins served as President and Chief Executive Officer and as a director of the Centre of Excellence in Personalized Medicine (CEPMED). From 1998 to 2007, Dr. Desjardins served as Senior Vice President, Corporate Development and a director at Caprion Pharmaceuticals Inc. (“Caprion”), which she co-founded. Prior to Caprion, Dr. Desjardins co-founded Advanced Bioconcept Inc. in 1992. She served there until 1998, most recently as Vice President, Business Development. Dr. Desjardins currently serves on the Board of Directors of BELLUS Health Inc. (Nasdaq: BLU; TSX: BLU) and Xenon Therapeutics (Nasdaq: XENE). Dr. Desjardins received a Bachelor of Science degree in Anatomical Sciences and History and Philosophy of Science and a Ph.D. in Neurology and Neurosurgery, each from McGill University in Montreal, Quebec, Canada. Dr. Desjardins was a Medical Research Council postdoctoral fellow at Douglas Hospital Research Centre at McGill University. Dr. Desjardins is chair of the Science & Technology Committee.

What is Clarissa Desjardins' net worth?: The estimated net worth of Clarissa Desjardins is at least $620.25 thousand as of May 21st, 2025. Desjardins owns 3,025 shares of Insmed stock worth more than $620,246 as of December 5th. This net worth estimate does not reflect any other assets that Desjardins may own. Learn More about Clarissa Desjardins' net worth.
How do I contact Clarissa Desjardins?: The corporate mailing address for Desjardins and other Insmed executives is 700 US Highway 202/206, Bridgewater NJ, 08807. Insmed can also be reached via phone at 908-977-9900 and via email at [email protected]. Learn More on Clarissa Desjardins' contact information.
Has Clarissa Desjardins been buying or selling shares of Insmed?: Clarissa Desjardins has not been actively trading shares of Insmed in the last ninety days. Most recently, on Wednesday, May 21st, Clarissa Desjardins bought 1,130 shares of Insmed stock. The stock was acquired at an average cost of $66.35 per share, with a total value of $74,975.50. Following the completion of the transaction, the director now directly owns 3,025 shares of the company's stock, valued at $200,708.75. Learn More on Clarissa Desjardins' trading history.
Who are Insmed's active insiders?: Insmed's insider roster includes Roger Adsett (COO), Elizabeth Anderson (Director), Sara Bonstein (CFO), David Brennan (Director), Clarissa Desjardins (Director), Clarissa Desjardins (Director), Martina Flammer (Insider), Leo Lee (Director), William Lewis (CEO), David McGirr (Director), Orlov Nicole Schaeffer (Insider), Melvin Sharoky (Director), Michael Smith (VP), and John Wise (Insider). Learn More on Insmed's active insiders.
Are insiders buying or selling shares of Insmed?: In the last year, Insmed insiders bought shares 2 times. They purchased a total of 3,025 shares worth more than $201,694.15. In the last year, insiders at the biopharmaceutical company sold shares 74 times. They sold a total of 1,482,921 shares worth more than $149,825,544.11. The most recent insider tranaction occured on November, 24th when Director Elizabeth M Anderson sold 5,000 shares worth more than $1,022,900.00. Insiders at Insmed own 3.0% of the company. Learn More about insider trades at Insmed.
Information on this page was last updated on 11/24/2025.

Clarissa Desjardins Insider Trading History at Insmed

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
5/21/2025	Buy	1,130	$66.35	$74,975.50	3,025
5/20/2025	Buy	1,895	$66.87	$126,718.65	1,895

Clarissa Desjardins Buying and Selling Activity at Insmed

Insmed Company Overview

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.

Today's Range

Now: $205.04

$202.68

$208.81

50 Day Range

MA: $179.16

$137.03

$211.41

2 Week Range

Now: $205.04

$60.40

$212.75

Volume

1,861,157 shs

Average Volume

2,592,626 shs

Market Capitalization

$43.73 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.01